Feature Healthcare Stocks Top News Monte Rosa’s Big Raise Shows Why Anti-Inflammatory Stories Are in Focus Eli Lilly’s buyout of Ventyx Biosciences (Nasdaq: VTYX) signaled that Big Pharma… Robin LeffertsJanuary 28, 2026
Feature Healthcare Stocks Top News Ventyx/Lilly Deal Shows the Value of Anti-inflammatory Drugs We wrote late last year about the recent upswing in big pharma… Robin LeffertsJanuary 15, 2026
Feature Healthcare Stocks Top News A Close Look at Cardiol Therapeutics’ Phase 2 Results Shows the Path Forward Not all clinical trial results are cut and dried. Sometimes the outcome… Robin LeffertsDecember 9, 2025
Feature Healthcare Stocks Top News Investor Opportunity: Big Pharma Patent Cliff Spurring Surge in M&A Activity Here’s the short version: Big pharma is staring down a real patent… Robin LeffertsNovember 18, 2025
Feature Healthcare Stocks Top News Cardiol Therapeutics’ Financing Paves Way for Heart Failure Drug Development Smaller pharmaceutical companies embark on an exciting journey as they seek to… Robin LeffertsOctober 29, 2025
Feature Healthcare Stocks Top News Phase II Results Point the Way Forward for Cardiol Therapeutics For smaller public company drug developers clinical trial results are major catalytic… Robin LeffertsSeptember 16, 2025
Feature Healthcare Stocks Understanding the Importance of Left Ventricular Mass in Heart Conditions Left ventricular (LV) mass has emerged as one of the most powerful… Robin LeffertsSeptember 15, 2025
Healthcare Stocks Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug… Ryan AllwayFebruary 20, 2025
Healthcare Stocks Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis Toronto, Ontario–(Newsfile Corp. – September 24, 2024) – Cardiol Therapeutics Inc. (NASDAQ:… Ryan AllwaySeptember 24, 2024
Feature Healthcare Stocks Top News Positive Phase 2 Results Signal Promising Future For Cardiol Therapeutics The future of smaller drug development companies frequently hinges on the results… Robin LeffertsJune 20, 2024
